Select a medication above to begin.
Cimzia
certolizumab pegol
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in patients with chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections including Legionella and Listeria observed; some infections have been fatal; most infections occur in combo with other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during certolizumab tx; initiate anti-TB tx before certolizumab tx; monitor for infection signs/symptoms during and after certolizumab tx; since active TB has developed in patients with negative tuberculin skin test, monitor all patients for active TB signs/symptoms; since histoplasmosis may be present in patients with negative antigen and antibody tests, consider empiric antifungal tx in patients with severe systemic illness if at risk for invasive fungal infection; D/C certolizumab tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers
Adult Dosing .
Dosage forms: INJ (pre-filled syringe): 200 mg per mL; INJ (vial): 200 mg per mL
Crohn disease, moderate-severe
- [400 mg SC q4wk]
- Start: 400 mg SC x1 on wk 0, 2, 4
rheumatoid arthritis, moderate-severe
- [200 mg SC q2wk or 400 mg SC q4wk]
- Start: 400 mg SC x1 on wk 0, 2, 4
psoriatic arthritis
- [200 mg SC q2wk or 400 mg SC q4wk]
- Start: 400 mg SC x1 on wk 0, 2, 4
ankylosing spondylitis
- [200 mg SC q2wk or 400 mg SC q4wk]
- Start: 400 mg SC x1 on wk 0, 2, 4
axial spondyloarthritis, non-radiographic
- [200 mg SC q2wk or 400 mg SC q4wk]
- Start: 400 mg SC x1 on wk 0, 2, 4
plaque psoriasis, moderate-severe
- [400 mg SC q2wk]
- Info: if wt <90 kg, may consider 400 mg SC x1 on wk 0, 2, 4, then 200 mg SC q2wk
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (pre-filled syringe): 200 mg per mL; INJ (vial): 200 mg per mL
polyarticular juvenile idiopathic arthritis
- [2 yo and older, 10-19.9 kg]
- Dose: 50 mg SC q2wk; Start: 100 mg SC x1 on wk 0, 2, 4
- [2 yo and older, 20-39.9 kg]
- Dose: 100 mg SC q2wk; Start: 200 mg SC x1 on wk 0, 2, 4
- [2 yo and older, >40 kg]
- Dose: 200 mg SC q2wk; Start: 400 mg SC x1 on wk 0, 2, 4
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, active
- caution: infection risk
- caution: patients >65 yo
- caution: infection, chronic
- caution: infection, recurrent
- caution: diabetes mellitus, uncontrolled
- caution: opportunistic infection history
- caution: TB infection, latent
- caution: TB infection risk
- caution: residents of area with endemic TB
- caution: travelers in area with endemic TB
- caution: residents of area with endemic mycosis
- caution: travelers in area with endemic mycosis
- caution: HBV infection
- caution: HBV infection history
- caution: malignancy history
- caution: malignancy risk
- caution: CHF
- caution: demyelinating disease
- caution: myelosuppression
- caution: myelosuppression history
- caution: hypersensitivity to latex (prefilled syringe form)
Drug Interactions .
Overview
certolizumab pegol
TNF blocker
- cardiotoxic effects
- immunomodulatory effects
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- anakinra
- anifrolumab
- baricitinib
- canakinumab
- certolizumab pegol
- cladribine oral
- deuruxolitinib
- epirubicin
- etanercept
- etrasimod
- golimumab
- idarubicin
- infliximab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- rilonacept
- ritlecitinib
- rituximab
- ruxolitinib topical
- sarilumab
- tocilizumab
- tofacitinib
- upadacitinib
- vedolizumab
Monitor/Modify Tx
- ado-trastuzumab emtansine
- aficamten
- aldesleukin
- alogliptin
- anagrelide
- anthrax vaccine
- asciminib
- avelumab
- axitinib
- bevacizumab
- bezlotoxumab
- binimetinib
- bortezomib
- bosutinib
- capecitabine
- carfilzomib
- chikungunya vaccine
- cilostazol
- clozapine
- cobimetinib
- COVID-19 vaccine
- cyclophosphamide
- dabrafenib
- daunorubicin
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- doxorubicin
- dronedarone
- ebola vaccine, live
- encorafenib
- entrectinib
- everolimus
- fam-trastuzumab deruxtecan
- fluorouracil
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- ibrutinib
- ifosfamide
- imatinib
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- itraconazole
- Japanese encephalitis vaccine
- lapatinib
- lenvatinib
- linagliptin
- margetuximab
- mavacamten
- meningococcal vaccine
- mirdametinib
- mitomycin
- mitoxantrone
- mobocertinib
- osimertinib
- pazopanib
- peginterferon beta 1a
- pegvaliase
- pertuzumab
- pioglitazone
- pneumococcal vaccine
- poliovirus vaccine
- ponatinib
- propafenone
- respiratory syncytial virus vaccine
- ripretinib
- ropeginterferon alfa-2b
- rosiglitazone
- saxagliptin
- selumetinib
- sipuleucel-T
- sitagliptin
- smallpox/mpox vaccine, live
- sorafenib
- sunitinib
- tick-borne encephalitis vaccine
- tivozanib
- trabectedin
- trametinib
- trastuzumab
- typhoid vaccine
- vandetanib
- zanidatamab
- zenocutuzumab
- zongertinib
Caution Advised
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- alemtuzumab
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- carboplatin
- carmustine
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- coccidioides immitis skin test antigen
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- eribulin
- etoposide
- etuvetidigene autotemcel
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- icotrokinra
- idecabtagene vicleucel
- idelalisib
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- narsoplimab
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rilzabrutinib
- risankizumab
- romidepsin
- rozanolixizumab
- ruxolitinib
- satralizumab
- secukinumab
- selinexor
- sibeprenlimab
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- topotecan
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vamorolone
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, serious
- opportunistic infection
- tuberculosis
- HBV reactivation
- malignancy
- lymphoma
- leukemia
- skin CA
- hypersensitivity reaction
- anaphylaxis
- skin reaction, severe
- CHF
- neurologic disorders
- optic neuritis
- myelosuppression
- lupus-like syndrome
- vasculitis
- sarcoidosis
- interstitial lung disease
- hepatotoxicity
Common Reactions
- URI
- rash
- UTI
- arthralgia
- headache
- HTN
- back pain
- fever
- fatigue
- infection, serious
- cough
- injection site reaction
Safety/Monitoring .
Monitoring Parameters
hepatitis B serology including HBsAg at baseline; TB test at baseline, then periodically; active TB signs/symptoms; dermatologic exams, especially if incr. skin CA risk
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; risk of teratogenicity not expected based on limited human data
Pregnancy Registry
enroll patients or encourage patients to enroll in MotherToBaby Pregnancy Studies at 1-877-311-8972 or at www.mothertobaby.org/pregnancy-studies/
Lactation
Clinical Summary
may use while breastfeeding; no known risk of infant harm based on limited human data and drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for certolizumab pegol: unknown; CYP450: unknown
Excretion: for certolizumab pegol: unknown; Half-life: 14 days
Subclass: DMARDs, Tumor Necrosis Factor (TNF) Inhibitors ; Inflammatory Bowel Disease (IBD) ; Psoriasis, Systemic Agents ; Spondyloarthropathies
Mechanism of Action
for certolizumab pegol: binds and inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: UCB Pharma, Inc.
DEA/FDA: Rx
Retail Price
Estimated prices only. For current pricing, visit GoodRx.
subcutaneous kit:
- 200 mg/vial (2 kit, 2 vials): $9,833.00
subcutaneous kit:
- 200 mg/mL (1 kit, 2 prefilled syringes of 1 mL): $4,922.00
subcutaneous kit:
- 200 mg/mL (1 kit, 6 prefillled syringes of 1 mL): $4,922.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.